Mochi Health Prescription Process: How It Works, What to Expect, and How It Compares

What Is Mochi Health and Is It Legitimate?

Mochi Health operates as a licensed telehealth practice. Physicians on its platform hold active state medical licenses, and every prescription issued must comply with the Ryan Haight Online Pharmacy Consumer Protection Act and applicable state telemedicine laws. The platform does not prescribe controlled substances in a way that bypasses federal prescribing rules.

Legitimacy in telehealth turns on three questions: Are the prescribers licensed? Are the drugs FDA-approved? Does the clinical intake meet a reasonable standard of care? For Mochi, the answer to all three appears to be yes, with caveats examined below.

Licensed Physicians, Not Algorithms

Prescriptions at Mochi are issued by physicians, not generated algorithmically. Patients upload a health intake form, and a licensed physician reviews it before any prescription is written. Some reviews are asynchronous (the physician reviews the chart on their own schedule and messages back within 24 to 48 hours), while others involve a live video visit.

FDA-Approved Medications Only

Mochi prescribes drugs with FDA approval or, in some cases, compounded versions of those drugs sourced through 503B outsourcing facilities. The distinction matters. FDA-approved semaglutide (Wegovy) and tirzepatide (Zepbound) have gone through rigorous Phase 3 trials. Compounded semaglutide, which some telehealth services use when brand-name supply is constrained, does not carry the same approval. The FDA issued a warning in 2024 noting that compounded semaglutide products are not FDA-approved and carry risks including dosing errors and contamination. Patients should confirm with Mochi at intake whether they are receiving brand-name or compounded product.

State Coverage

Mochi operates in most US states. Because telemedicine prescribing rules differ by state, patients in a small number of states may face restrictions on which drugs can be prescribed remotely on an initial visit.

How the Intake and Prescription Process Works Step by Step

The Mochi intake process is designed to be completed entirely online. Below is a clinical-level walkthrough of what actually happens at each stage.

Step 1: Online Health Questionnaire (5 to 10 Minutes)

The patient completes a structured intake form covering current weight, height, medical history, current medications, and relevant lab work if available. This is not a casual symptom checker. The form maps to standard clinical screening questions used to determine eligibility for GLP-1 therapy under the FDA's approved indications.

FDA labeling for semaglutide (Wegovy) requires a BMI ≥30, or BMI ≥27 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. Tirzepatide (Zepbound) carries the same BMI thresholds per its 2023 FDA approval label.

Contraindications the questionnaire screens for include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pancreatitis, all listed in the Wegovy prescribing information (FDA label, 2021).

Step 2: Physician Chart Review

A licensed Mochi physician reviews the intake. This step separates a telehealth prescription platform from a direct-to-consumer supplement company. The physician may:

• Approve the patient for treatment and select an initial medication and dose
• Request additional lab work (common for patients with type 2 diabetes or renal concerns)
• Schedule a synchronous video visit for cases requiring more clinical detail
• Decline to prescribe if contraindications are present

Turnaround is typically 24 to 48 hours for asynchronous review.

Step 3: Prescription Transmission and Pharmacy Fulfillment

Approved prescriptions are sent electronically to a pharmacy. Mochi works with specialty pharmacies that can handle brand-name GLP-1 pens and, where relevant, compounded formulations. Patients receive tracking information and instructions on injection technique.

Step 4: Ongoing Clinical Management

GLP-1 therapy is not a single prescription. Dose titration is required. Wegovy's titration schedule begins at 0.25 mg semaglutide weekly for 4 weeks, advancing through 0.5 mg, 1 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose over 16 to 20 weeks, per the approved prescribing information. Mochi providers manage this titration through follow-up messages or visits.

Patients who experience side effects, particularly nausea, vomiting, or gastrointestinal distress (which affected 44% of semaglutide participants vs. 16% of placebo in STEP-1 [1]), can message their care team for dose adjustments or temporary holds.

What Does Mochi Health Prescribe?

Mochi's formulary centers on GLP-1 receptor agonists, the drug class with the strongest clinical evidence base for chronic weight management in adults with obesity.

Semaglutide (Wegovy and Ozempic)

Semaglutide is the most prescribed medication in Mochi's formulary. In STEP-1 (N=1,961), once-weekly semaglutide 2.4 mg produced a mean 14.9% reduction in body weight at 68 weeks compared to 2.4% with placebo (P<0.001) [1]. The STEP-4 trial (N=803) showed that discontinuation of semaglutide after 20 weeks led to regain of approximately two-thirds of the lost weight within 48 weeks [2], a finding with direct implications for how long patients should expect to remain on therapy.

Ozempic (semaglutide 0.5 mg to 2 mg) is FDA-approved for type 2 diabetes but is sometimes prescribed off-label for weight management in patients who also have diabetes, though Wegovy carries the obesity indication.

Tirzepatide (Zepbound and Mounjaro)

Tirzepatide, a dual GIP and GLP-1 receptor agonist, is available through Mochi where supply allows. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced a mean 20.9% reduction in body weight at 72 weeks compared to 3.1% with placebo (P<0.001) [3]. That 20.9% figure is clinically meaningful: it approaches the weight loss seen with bariatric surgery in some cohorts.

Other Medications

For patients who do not meet GLP-1 eligibility criteria, or who cannot tolerate these agents, Mochi physicians may prescribe:

• Bupropion/naltrexone (Contrave), FDA-approved for chronic weight management
• Phentermine/topiramate (Qsymia), FDA-approved with REMS program requirements
• Metformin, used off-label in pre-diabetic patients with obesity per some endocrinology guidelines

How Much Does Mochi Health Cost?

Cost is the most common concern raised in patient reviews. The pricing structure has two layers: the platform membership fee and the medication cost.

Platform Membership

Mochi charges approximately $99 per month for its membership, which covers provider access, clinical consultations, and care coordination. This fee is separate from medication costs and is generally not covered by insurance.

Medication Costs and Insurance Billing

Mochi's model explicitly includes insurance billing, which distinguishes it from some competitors that operate cash-pay only. For patients with commercial insurance that covers Wegovy or Zepbound, out-of-pocket costs can drop significantly. Novo Nordisk's Wegovy has a list price above $1,300 per month, but with insurance and manufacturer savings cards, some patients pay as little as $25 per month (Novo Nordisk's WeGoTogether savings program, though eligibility is income and insurance dependent).

Without insurance, brand-name semaglutide 2.4 mg runs roughly $1,000 to $1,350 per month. Compounded semaglutide through 503B pharmacies may be offered at $200 to $400 per month, though patients should weigh the regulatory cautions above.

What the Total Cost Looks Like

A patient paying cash for the platform plus brand-name medication could spend $1,100 to $1,450 per month. A patient with strong insurance coverage plus the manufacturer savings card could spend $124 to $200 per month total. The spread is wide. Patients should verify their specific plan's formulary before enrolling.

Mochi Health vs. Alternatives: A Clinical Comparison

The GLP-1 telehealth space includes at least a dozen platforms. The table below compares Mochi against four major competitors on clinically relevant dimensions.

| Platform | Insurance Billing | Medications Offered | Prescribing Model | Approx. Monthly Fee | |---|---|---|---|---| | Mochi Health | Yes | Semaglutide, tirzepatide, Contrave, Qsymia | Async physician review | ~$99 | | Calibrate | Yes | Semaglutide, tirzepatide | Sync video visits | ~$199 | | Found | Limited | Semaglutide, bupropion/naltrexone, others | Async physician | ~$99 | | Ro Body | No (cash-pay) | Semaglutide (brand + compounded) | Async physician | ~$145 | | WeightWatchers Clinic | Partial | Semaglutide, tirzepatide | Video visits | ~$84 clinic fee |

Where Mochi Stands Out

Mochi's dual-path billing (insurance and cash-pay) gives it a practical advantage for patients whose insurance covers GLP-1s. Calibrate also offers insurance billing but charges roughly double the monthly platform fee. Found has a similar price point but a more limited formulary for GLP-1s in some states.

Where Mochi Falls Short

Asynchronous-first care models move faster but can miss clinical nuance. A 2022 JAMA Health Forum analysis found that telehealth obesity visits relying on asynchronous messaging had lower rates of metabolic lab follow-up compared to synchronous video visits [4]. Patients with complex metabolic histories, including those with type 2 diabetes, cardiovascular disease, or a history of pancreatitis, may benefit from a platform that defaults to synchronous physician visits.

The Compounded Semaglutide Question

Several platforms, including some Mochi patients report receiving, have offered compounded semaglutide during periods of Wegovy shortage. The FDA placed semaglutide on the shortage list in 2022 and 2023. By early 2025, the FDA declared the semaglutide shortage resolved and signaled that compounding pharmacies should wind down production. Patients currently on compounded semaglutide through any platform should confirm their transition pathway to the approved drug.

Clinical Evidence Behind GLP-1 Therapy: Why These Drugs Are Prescribed

Mochi's entire clinical model rests on the evidence base for GLP-1 receptor agonists in obesity. That evidence is now substantial.

Weight Loss Efficacy

STEP-1 established semaglutide 2.4 mg as the benchmark: 14.9% mean weight loss at 68 weeks [1]. SURMOUNT-1 raised the ceiling with tirzepatide 15 mg at 20.9% [3]. For context, the American Academy of Clinical Endocrinology (AACE) 2023 guidelines state that "pharmacotherapy is recommended as an adjunct to lifestyle intervention for patients with BMI ≥30 or BMI ≥27 with weight-related complications" [5].

Cardiovascular Benefit

The SELECT trial (N=17,604), published in the New England Journal of Medicine in 2023, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) [6]. This was the first cardiovascular outcomes trial for a GLP-1 agent in non-diabetic patients with obesity, and it shifted prescribing practice considerably.

Long-Term Use Expectations

The STEP-4 data [2] make one thing clinically plain: weight regain after stopping semaglutide is real and substantial. This means any prescribing platform, Mochi included, should be having explicit conversations about treatment duration with patients at intake, not just at year two. A platform that does not address long-term continuation planning is not providing a complete standard of care.

What Real Patients Should Know Before Starting

Patients researching Mochi typically arrive after seeing advertising that emphasizes access and affordability. The clinical reality is more nuanced.

Eligibility Is Not Guaranteed

Not every patient who completes the Mochi intake will receive a prescription. Physicians decline to prescribe when contraindications are present. Patients with a personal or family history of thyroid cancer, those currently on certain psychiatric medications with interaction risks, or those with active eating disorders may be declined or referred to in-person care.

Side Effects Are Common and Dose-Dependent

Nausea affects the majority of patients starting GLP-1 therapy. In STEP-1, 44% of semaglutide participants reported nausea versus 16% on placebo [1]. Most nausea is transient and improves after the first 4 to 8 weeks. Titrating slowly and eating smaller, lower-fat meals reduces severity. The Mochi care team can adjust the titration schedule if side effects are limiting adherence.

Lab Monitoring Is Part of Good Practice

Some telehealth platforms skip lab work entirely. The AACE 2023 obesity guidelines recommend baseline metabolic panel, lipid profile, and HbA1c before initiating pharmacotherapy. Patients should ask their Mochi provider explicitly whether labs are required or recommended before their first prescription is filled.

Insurance Approval Takes Time

Even when a patient is clinically eligible and a prescription is written, insurance prior authorization for Wegovy or Zepbound can take 1 to 3 weeks and may be denied on the first attempt. Mochi's care team assists with prior authorization paperwork, but patients should build in this timeline when starting.